<DOC>
	<DOCNO>NCT00006200</DOCNO>
	<brief_summary>The purpose clinical trial ass activity thalidomide combination dacarbazine ( DTIC ) patient metastatic melanoma . Safety toxicity two drug also assess . Dacarbazine standard medical treatment metastatic melanoma . It show produce tumor shrinkage approximately 20 % patient advanced melanoma . This shrinkage usually incomplete last short time . Thalidomide drug inhibits tumor blood vessel growth . It give orally . It hop combination give patient metastatic melanoma without cause much toxicity increase response rate .</brief_summary>
	<brief_title>Thalidomide Dacarbazine Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Patients metastatic melanoma . Lesions must measurable . Patient must follow minimum lab : ANC &gt; 1500/mm3 , Hemoglobin &gt; 8 mg/dl ; platelet &gt; 100,000 mm3 ; liver function test &lt; 5x normal ; creatinine &lt; 1.5 mg/dl . ECOG performance status &gt; 2 . No prior therapy DTIC thalidomide No history malignancy curatively resect basal cell carcinoma skin carcinoma situ cervix . Patients must pregnant lactating . Sexually active men woman childbearing age must use adequate contraception . All patient must understand potential severe birth defect thalidomide must able follow instruction avoid conception take thalidomide</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2004</verification_date>
</DOC>